Gene: CYP2A7

1549
CPA7|CPAD|CYP2A|CYPIIA7|P450-IIA4
cytochrome P450 family 2 subfamily A member 7
protein-coding
19q13.2
Ensembl:ENSG00000198077 MIM:608054 Vega:OTTHUMG00000182715 UniprotKB:P20853
NG_007960.1
PubMed|SNP Mapped
1   ANCO-SNPs
ND
13   
NA (AD)  NA (ND)   (Frontal_Cortex)
3.306e-1 (AD)  8.626e-3 (ND)

ANCO-SNPs

SNP ID Position Alleles Trait Variation Type
rs4079366chr19:40878770 (GRCh38.p7)T>A / T>Cnicotine dependenceSNV(Single Nucleotide Variation)

DNA Methylation

There is no related methylation information for this gene.

Gene Expression in Different Tissues

Temporal and Spatial Expressions (BrainSpan)

Footnote:
SC: sub-cortical regions; SM: sensory-motor regions; FC: frontal cortex; and TP: temporal-parietal cortex
ST1: fetal (13 - 26 postconception weeks), ST2: early infancy to late childhood (4 months to 11 years), and ST3: adolescence to adulthood (13 - 23 years)
The bar shown representes average value of the expressions.

Top Co-expressed Genes in Brain-Frontal Cortex (BA9) (GTEx v7)

Top 10 positively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
PRSS480.531
SPDYE10.466
ERVW-10.461
KCNQ1OT10.459
ACMSD0.451
CDHR50.443
CYP2A60.428
FAM186B0.424
DAO0.417
TSPAN320.411

Top 10 negatively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
HIST1H3C-0.253
EFNA4-0.245
NAT1-0.238
IL18R1-0.232
MTHFD2-0.23
RPL10L-0.228
CLEC2B-0.222
GRAP-0.22
ADM5-0.218
LYVE1-0.217

Drugs/Compounds

    There is no DrugBank record for this gene !

ID Drug Name Action PubMed
C0284741,4-bis(2-(3,5-dichloropyridyloxy))benzene"1,4-bis(2-(3,5-dichloropyridyloxy))benzene promotes the reaction [[Anisomycin co-treated with NR1I3 protein] results in increased expression of CYP2A7 mRNA]"23539296
D016604Aflatoxin B1Aflatoxin B1 affects the expression of CYP2A7 protein20106945
D016604Aflatoxin B1Aflatoxin B1 results in decreased expression of CYP2A7 mRNA27153756
D016604Aflatoxin B1Aflatoxin B1 results in decreased methylation of CYP2A7 gene27153756
D000841Anisomycin"1,4-bis(2-(3,5-dichloropyridyloxy))benzene promotes the reaction [[Anisomycin co-treated with NR1I3 protein] results in increased expression of CYP2A7 mRNA]"23539296
D000841Anisomycin[Anisomycin co-treated with NR1I3 protein] results in increased expression of CYP2A7 mRNA23539296
D001564Benzo(a)pyreneBenzo(a)pyrene results in decreased expression of CYP2A7 mRNA20106945
D004958EstradiolEstradiol results in decreased expression of CYP2A7 mRNA20106945
D020111Chlorodiphenyl (54% Chlorine)Chlorodiphenyl (54% Chlorine) results in increased expression of CYP2A7 mRNA17851650
D016572CyclosporineCyclosporine results in decreased expression of CYP2A7 mRNA20106945
D003671DEETDEET results in increased expression of CYP2A7 mRNA27091632
D003671DEET[fipronil co-treated with DEET] results in increased expression of CYP2A7 mRNA27091632
D002117CalcitriolCalcitriol results in increased expression of CYP2A7 mRNA21592394
D002117Calcitriol[Testosterone co-treated with Calcitriol] results in increased expression of CYP2A7 mRNA21592394
D004128DimethylnitrosamineCYP2A7 protein results in increased metabolism of and results in increased activity of Dimethylnitrosamine11960914
D004391DustDust results in decreased expression of CYP2A7 mRNA17805423
D004726Endosulfan[Endosulfan co-treated with Tetrachlorodibenzodioxin] results in decreased expression of CYP2A7 mRNA26159488
C082360fipronil[fipronil co-treated with DEET] results in increased expression of CYP2A7 mRNA27091632
D006830Hydralazine[Hydralazine co-treated with Valproic Acid] results in increased expression of CYP2A7 mRNA17183730
D008748MethylcholanthreneMethylcholanthrene promotes the reaction [AHR protein binds to CYP2A7 promoter]20348232
D010634PhenobarbitalPhenobarbital results in increased expression of CYP2A7 mRNA19084549
C089730rosiglitazonerosiglitazone results in decreased expression of CYP2A7 mRNA25572481
D013739Testosterone[Testosterone co-treated with Calcitriol] results in increased expression of CYP2A7 mRNA21592394
D013739TestosteroneTestosterone results in increased expression of CYP2A7 mRNA21592394
D013749Tetrachlorodibenzodioxin[Endosulfan co-treated with Tetrachlorodibenzodioxin] results in decreased expression of CYP2A7 mRNA26159488
C057693troglitazonetroglitazone results in decreased expression of CYP2A7 mRNA25572481
D014635Valproic Acid[Hydralazine co-treated with Valproic Acid] results in increased expression of CYP2A7 mRNA17183730

GO/Pathway

GO ID GO Term Qualifier Evidence PubMed
GO:0005506iron ion binding-IEA-  
GO:0008392arachidonic acid epoxygenase activity-IBA21873635  
GO:0008395steroid hydroxylase activity-IBA21873635  
GO:0016712oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen-IBA21873635  
GO:0019825oxygen binding-TAS7864805  
GO:0020037heme binding-IBA21873635  
GO:0020037heme binding-IEA-  
GO:0070330aromatase activity-IEA-  
GO ID GO Term Qualifier Evidence PubMed
GO:0006082organic acid metabolic process-IBA21873635  
GO:0006805xenobiotic metabolic process-IBA21873635  
GO:0009804coumarin metabolic process-IBA21873635  
GO:0042738exogenous drug catabolic process-IBA21873635  
GO:0055114oxidation-reduction process-IBA21873635  
GO:0055114oxidation-reduction process-IEA-  
GO ID GO Term Qualifier Evidence PubMed
GO:0005737cytoplasm-IBA21873635  
GO:0005789endoplasmic reticulum membrane-IEA-  
GO:0031090organelle membrane-IEA-  
GO:0043231intracellular membrane-bounded organelle-IBA21873635  
KEGG ID KEGG Term
hsa00232Caffeine metabolism
hsa00830Retinol metabolism
hsa00982Drug metabolism - cytochrome P450
hsa00983Drug metabolism - other enzymes
hsa01100Metabolic pathways
Reactome ID Reactome Term Evidence
R-HSA-1430728MetabolismTAS
R-HSA-211859Biological oxidationsTAS
R-HSA-211897Cytochrome P450 - arranged by substrate typeTAS
R-HSA-211935Fatty acidsTAS
R-HSA-211945Phase I - Functionalization of compoundsTAS
R-HSA-211981XenobioticsTAS
R-HSA-211999CYP2E1 reactionsTAS

Interactions (STRING v10.5, Interaction Score >= 0.400)

Publications (Co-occurrence of gene symbol strings and ANCO-Dependence terms)

PMID Title (Year) Author Journal
25532948Genotyping of wild-type cytochrome P450 2A6 and whole-gene deletion using human blood samples and a multiplex real-time polymerase chain reaction method with dual-labeled probes. (2015 Feb 20)Shimizu MClin Chim Acta
10544257Identification and characterisation of novel polymorphisms in the CYP2A locus: implications for nicotine metabolism. (1999 Oct 29)Oscarson MFEBS Lett
26407342A Genome-Wide Association Study of a Biomarker of Nicotine Metabolism. (2015)Loukola APLoS Genet
22706231CYP2A6: genetics, structure, regulation, and function. (2012 May 5)Raunio HDrug Metabol Drug Interact
29767774Common and rare variants genetic association analysis of cigarettes per day among ever smokers in COPD cases and controls. (2018 May 15)Lutz SMNicotine Tob Res
25446842Single tube genotyping of CYP2A6 gene deletion based on copy number determination by quantitative real-time PCR. (2014 Dec)Liu JHExp Mol Pathol
17267622A novel duplication type of CYP2A6 gene in African-American population. (2007 Apr)Fukami TDrug Metab Dispos
10217419Characterisation and PCR-based detection of a CYP2A6 gene deletion found at a high frequency in a Chinese population. (1999 Apr 1)Oscarson MFEBS Lett
21420395Direct genotyping of Cytochrome P450 2A6 whole gene deletion from human blood samples by the SmartAmp method. (2011 Jun 11)Azuma KClin Chim Acta
163786013'-UTR polymorphism in the human CYP2A6 gene affects mRNA stability and enzyme expression. (2006 Feb 10)Wang JBiochem Biophys Res Commun
27113016Genome-Wide Association of the Laboratory-Based Nicotine Metabolite Ratio in Three Ancestries. (2016 Sep)Baurley JWNicotine Tob Res
20136358New CYP2A6 gene deletion and conversion variants in a population of Black African descent. (2010 Feb)Mwenifumbo JCPharmacogenomics
11393269Determination of coumarin metabolism in Turkish population. (2001 Apr)Cok IHum Exp Toxicol